NO980592L - Nye opioidpeptider - Google Patents

Nye opioidpeptider

Info

Publication number
NO980592L
NO980592L NO980592A NO980592A NO980592L NO 980592 L NO980592 L NO 980592L NO 980592 A NO980592 A NO 980592A NO 980592 A NO980592 A NO 980592A NO 980592 L NO980592 L NO 980592L
Authority
NO
Norway
Prior art keywords
peptides
pain
opioid
preparation
opioid peptides
Prior art date
Application number
NO980592A
Other languages
English (en)
Other versions
NO980592D0 (no
Inventor
Wuyi Wang
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502877A external-priority patent/SE9502877D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO980592L publication Critical patent/NO980592L/no
Publication of NO980592D0 publication Critical patent/NO980592D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nye opioidpeptider for behandling av smerte samt en fremgangsmåte for fremstilling derav og farmasøytisk akseptable preparater omfattende disse peptidene. Det er også beskrevet metoder for bekjempelse av smerte hos pasienter ved bruk av preparater ifølge oppfinnelsen og anvendelse av nevnte forbindelser i fremstillingen av formuleringer som er effektive i smertebehandling. Peptidene har en høy grad av selektivitet for u- opioidreseptoren. Peptidene er særlig velegnet som analgetiske midler som virker vesentlig på perifere u-opioidreseptorer. Fordi disse peptidene virker perifert unngår de vesentlig utøvelse av bivirkninger som normalt er forbundet med sentral analgetisk virkning.
NO980592A 1995-08-18 1998-02-11 Nye opioidpeptider NO980592D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9502877A SE9502877D0 (sv) 1995-08-18 1995-08-18 Novel opioid peptides
SE9503924A SE9503924D0 (sv) 1995-08-18 1995-11-07 Novel opioid peptides
PCT/SE1996/001011 WO1997007130A1 (en) 1995-08-18 1996-08-14 Novel opioid peptides

Publications (2)

Publication Number Publication Date
NO980592L true NO980592L (no) 1998-02-11
NO980592D0 NO980592D0 (no) 1998-02-11

Family

ID=26662362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980592A NO980592D0 (no) 1995-08-18 1998-02-11 Nye opioidpeptider

Country Status (27)

Country Link
US (1) US6337319B1 (no)
EP (1) EP0845003B1 (no)
JP (1) JPH11512086A (no)
KR (1) KR19990037677A (no)
CN (1) CN1200127A (no)
AR (1) AR003475A1 (no)
AT (1) ATE210148T1 (no)
AU (1) AU711862B2 (no)
BR (1) BR9610248A (no)
CA (1) CA2229797A1 (no)
CZ (1) CZ287299B6 (no)
DE (1) DE69617699T2 (no)
DK (1) DK0845003T3 (no)
EE (1) EE9800048A (no)
ES (1) ES2171224T3 (no)
HU (1) HUP9901209A3 (no)
IL (1) IL123258A (no)
IS (1) IS4664A (no)
NO (1) NO980592D0 (no)
NZ (1) NZ315809A (no)
PL (1) PL325113A1 (no)
RU (1) RU2165432C2 (no)
SE (1) SE9503924D0 (no)
SK (1) SK282469B6 (no)
TR (1) TR199800258T1 (no)
TW (1) TW424095B (no)
WO (1) WO1997007130A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032774A1 (en) * 1994-02-21 2003-02-13 Astrazeneca Ab Novel opioid peptides for the treatment of pain
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
SE9701718D0 (sv) * 1997-05-07 1997-05-07 Astra Ab Analgesic peptidomimetic compounds
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
WO2001013938A1 (fr) * 1999-08-25 2001-03-01 Daiichi Fine Chemical Co., Ltd. Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses
AU1623801A (en) 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
AU2001277908A1 (en) 2000-07-18 2002-01-30 Cornell Research Foundation Inc. Medicinal uses of mu-opioid receptor agonists
JP2002069059A (ja) * 2000-08-28 2002-03-08 Teikoku Seiyaku Co Ltd ピラジノン環を含む新規なオピオイドペプチド誘導体
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006132925A2 (en) 2005-06-01 2006-12-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
EP1782819A1 (en) 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
BRPI0718651B8 (pt) 2006-11-10 2021-05-25 Cara Therapeutics Inc amidas peptídicas sintéticas
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
LT2273983T (lt) * 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
AU2010275754B2 (en) * 2009-07-22 2014-05-15 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
LT2736497T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102964279B (zh) * 2012-12-12 2014-05-07 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE136905T1 (de) * 1988-06-30 1996-05-15 Astra Ab Dermorphin-analoge, deren herstellungsverfahren, pharmazeutische zusammensetzungen und methode zur therapeutischen behandlung unter verwendung der analoge
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Also Published As

Publication number Publication date
DE69617699D1 (de) 2002-01-17
IL123258A (en) 2003-03-12
PL325113A1 (en) 1998-07-06
DK0845003T3 (da) 2002-07-15
IS4664A (is) 1998-02-04
CZ40198A3 (cs) 1998-08-12
US6337319B1 (en) 2002-01-08
AU6760096A (en) 1997-03-12
AR003475A1 (es) 1998-08-05
EP0845003A1 (en) 1998-06-03
WO1997007130A1 (en) 1997-02-27
NO980592D0 (no) 1998-02-11
CA2229797A1 (en) 1997-02-27
HUP9901209A3 (en) 2000-12-28
EE9800048A (et) 1998-08-17
CZ287299B6 (en) 2000-10-11
DE69617699T2 (de) 2003-08-07
NZ315809A (en) 1999-05-28
BR9610248A (pt) 1999-07-06
EP0845003B1 (en) 2001-12-05
AU711862B2 (en) 1999-10-21
TR199800258T1 (xx) 1998-05-21
IL123258A0 (en) 1998-09-24
JPH11512086A (ja) 1999-10-19
ATE210148T1 (de) 2001-12-15
SE9503924D0 (sv) 1995-11-07
SK282469B6 (sk) 2002-02-05
KR19990037677A (ko) 1999-05-25
HUP9901209A2 (hu) 1999-08-30
CN1200127A (zh) 1998-11-25
RU2165432C2 (ru) 2001-04-20
TW424095B (en) 2001-03-01
SK20398A3 (en) 1998-12-02
ES2171224T3 (es) 2002-09-01

Similar Documents

Publication Publication Date Title
NO980592L (no) Nye opioidpeptider
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ES2133785T3 (es) Inhibidores de metaloproteinasas.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
BR9506847A (pt) Composto composição farmacêutica uso de um composto processo para o tratamento da dor
HUP0103078A2 (hu) Készítmények és eljárások szürkehályog kezelésére
BR0313388A (pt) Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
ES2189252T3 (es) Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide.
MX9200728A (es) Formulacion farmaceutica adaptada para administracformulacion farmaceutica adaptada para administracion topica, para desordenes en la piel. ion topica, para desordenes en la piel.
DK0946162T3 (da) Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
PT883401E (pt) Antagonista do receptor at1 para estimulacao da apoptose
BG105434A (en) Sertraline oral concentrate
CO5590922A2 (es) Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
GB9930085D0 (en) Medicaments
MY124089A (en) Use of cetirizine for preventing the onset of asthma
SE9502877D0 (sv) Novel opioid peptides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application